Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow PaxMedica, Inc.

Get SEC filing alerts via email and in your feed for PaxMedica, Inc.

PXMD

PaxMedica, Inc.

About PaxMedica, Inc.

Paxmedica Inc. is a biopharmaceutical company developing anti-purinergic drug therapies for neurological and neurodevelopmental disorders, including autism spectrum disorder, Fragile X syndromes, and chronic fatigue syndrome. Its lead candidate, PAX-101 (intravenous suramin), targets core symptoms and infectious diseases like African sleeping sickness. The company focuses on innovative drug delivery, clinical trials, and intellectual property to address unmet medical needs in neurology.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from PaxMedica, Inc.

1
1
PaxMedica, Inc. Kuvatris Therapeutics Reports $7.6 Million Net Loss and Declining Liquidity in Latest Filing

Via official filing (AI summary) | 5 months ago | 0 comments

2
1
PaxMedica, Inc. PaxMedica Reports Net Loss of $6.7M, Decrease in Operating Expenses, and Cash Deterioration in 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments